Early CRISPR Trial Shows Promise for Sickle Cell Disease
Researchers have reported encouraging early results from a Phase 1/2 clinical trial of a new CRISPR-based gene-editing therapy for sickle cell disease, offering fresh hope for patients living with the inherited blood disorder.Promising Early OutcomesAccording to the study, treated patients showed sustained production of fetal hemoglobin, a form of hemoglobin that can help prevent red blood cells from becoming rigid…
علم ۲۰ بازدید ۱۳۶ روز پیش